<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963973</url>
  </required_header>
  <id_info>
    <org_study_id>RDN-929-103</org_study_id>
    <nct_id>NCT03963973</nct_id>
  </id_info>
  <brief_title>A 28 Day Parallel Group Study to Assess the Effects of RDN-929</brief_title>
  <official_title>A Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Multiple Oral Doses of RDN-929 in Healthy Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligibility will be assessed during a screening period of up to 4 weeks. Subjects will take
      study medication once daily up to and including Day 28. Safety, tolerability and PK will be
      measured at each visit.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Participants no longer receiving intervention
  </why_stopped>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Actual">January 22, 2020</completion_date>
  <primary_completion_date type="Actual">January 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>Screening to end of study, up to 9 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Physical exam findings</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>Screening to end of study, up to 9 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Clinical safety lab changes</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>Screening to end of study, up to 9 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Systolic blood pressure changes</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>Screening to end of study, up to 9 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Heart rate changes</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>Screening to end of study, up to 9 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with 12 Lead ECG changes</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>Screening to end of study, up to 9 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration, Cmax</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>RDN-929 and primary metabolite ROD-1610</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the plasma and CSF concentration time curve, AUC</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>RDN-929 and primary metabolite ROD-1610</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>RDN-929</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low, medium and high dose of RDN-929 capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDN-929 oral capsule</intervention_name>
    <description>low, medium and high dose</description>
    <arm_group_label>RDN-929</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>matching placebo dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males or postmenopausal or surgically sterile females age 55 - 85 years old.

          -  Healthy as determined by the Investigator, based on a medical evaluation including
             medical history, physical examination, neurological examination, laboratory tests and
             ECG recording

        Exclusion Criteria:

          -  Any history of major psychiatric disorders, including substance use disorders,
             according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
             (DSM-5) criteria

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than
             1.5 times the upper limit of normal (ULN)

          -  A clinically significant abnormality on physical examination, neurological
             examination, ECG, or laboratory evaluations

          -  A clinically significant vital signs abnormality, as judged by the principal
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>QPS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brain Research Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS Netherlands B.V.</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

